A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891).

Kunle Odunsi,Mihaela C. Cristea,Oliver Dorigo,Amir A. Jazaeri,Brian M. Slomovitz,Karen Chagin,Erin Van Winkle,Gabor Kari,Malini Iyengar,Elliot Norry,Arundathy N. Bartlett-Pandite,Rafael G. Amado

A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891).

2017

Kunle Odunsi
Mihaela C. Cristea
Oliver Dorigo
Amir A. Jazaeri
Brian M. Slomovitz
Karen Chagin
Erin Van Winkle
Gabor Kari
Malini Iyengar
Elliot Norry
Arundathy N. Bartlett-Pandite
Rafael G. Amado

TPS3094Background: Epithelial ovarian cancer comprises the majority of malignant ovarian neoplasms (~80%) and is the leading cause of death from gynecologic cancer in the US. Due to lack of effecti...

Keywords:

Refractory
Clinical trial
Ovarian cancer
Autologous T-cells
NY-ESO-1
Pathology
Oncology
Internal medicine
Medicine
open label
in patient
treatment refractory
Cause of death

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations